Novo Nordisk (NYSE: NVO)
Novo Nordisk Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Novo Nordisk Company Info
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
News & Analysis
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
The addressable market for the treatments could potentially contract significantly.
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Shareholders don't have too much to fear -- yet.
2 No-Brainer Healthcare Stocks to Buy With $1,000
There are no certainties in equity markets, but these stocks look highly likely to deliver outsized returns.
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
Ozempic remains on top in the GLP-1 drug market -- but for how long?
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
This list of top-selling drugs could look drastically different in a few years.
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
Novo Nordisk still expects to see a lot more growth in the second half.
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
There's reason to believe some of its expected revenue will take longer to arrive.
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
The company's addressable market could eventually be expanded even more.
Valuation
Earnings Transcripts
Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript
NVO earnings call for the period ending June 30, 2024.
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
NVO earnings call for the period ending March 31, 2024.
Novo Nordisk (NVO) Q4 2023 Earnings Call Transcript
NVO earnings call for the period ending December 31, 2023.
Novo Nordisk (NVO) Q3 2023 Earnings Call Transcript
NVO earnings call for the period ending September 30, 2023.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.